Literature DB >> 26835182

The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis.

Anagha Nadkarni1, Min You1, Holly Resuehr2, Jeffrey R Curtis2.   

Abstract

OBJECTIVES: To determine, using data from a real-world setting, the overall and sex-specific risk of cardiovascular (CV) events in patients with rheumatoid arthritis (RA), with or without comorbid hyperlipidemia, relative to those in a non-RA cohort.
METHODS: This retrospective cohort study using claims data from a US commercial health plan (2005-2011) included patients with RA and a matched non-RA cohort. Cox proportional hazards regression model determined the hazard ratio (HR) for CV events (myocardial infarction, stroke, revascularization procedures), using the presence of RA and hyperlipidemia as the independent variables, controlling for other covariates (age, sex, diabetes, and hypertension).
RESULTS: The incidence of CV events per 1000 person-years was 10.19 for the RA cohort and 6.41 for the non-RA cohort (crude rate ratio [RR] =1.59). Within the RA cohort, incidence was 15.54 for patients with hyperlipidemia and 7.05 for patients without hyperlipidemia (crude RR=2.21); in the non-RA cohort, incidence was 10.55 and 3.82 for those with and without hyperlipidemia, respectively (crude RR=2.76). After controlling for covariates, the HR of CV events among RA patients was 1.68 (95% CI: 1.50, 1.87) relative to non-RA patients. After multivariable adjustment, hyperlipidemia conferred a significant risk of CV events in both RA and non-RA patients; the interaction between RA and hyperlipidemia was not significant (p=0.13).
CONCLUSION: This real-world analysis demonstrates that patients with RA have an increased risk of CV events. Similar to a non-RA cohort, CV event rates were incrementally higher for those patients with hyperlipidemia. SIGNIFICANCE: Cardiovascular disease is an increasingly visible topic of concern in the rheumatoid arthritis community. However, there are only limited data that informs both the absolute and relative rates of CVD events, and the contribution of various risk factors such as hyperlipidemia, compared to non-RA populationsThe 'lipid paradox' hypothesis in RA suggests that elevated LDL cholesterol has a negligible effect on CVD risk in RA, unlikely in the general population where it is a well-accepted CVD risk factorThe incidence of CVD events in RA patients was 10/1000 patient years, a 1.6 fold greater risk compared to non-RA patientsThe contribution of hyperlipidemia to CVD risk was associated with comparable or greater absolute increases in the rate of CV events compared to non RA patients, a finding that does not support the lipid paradox.

Entities:  

Keywords:  Cardiovascular disease; Hyperlipidemia; Inflammation; Rheumatoid arthritis

Year:  2015        PMID: 26835182      PMCID: PMC4727537          DOI: 10.4172/2167-7921.1000178

Source DB:  PubMed          Journal:  J Arthritis        ISSN: 2167-7921


  19 in total

1.  Patterns of cardiovascular risk in rheumatoid arthritis.

Authors:  D H Solomon; N J Goodson; J N Katz; M E Weinblatt; J Avorn; S Setoguchi; C Canning; S Schneeweiss
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

2.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

Review 3.  A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis.

Authors:  Eduardo Nicolas Pollono; Maria A Lopez-Olivo; Juan Antonio Martinez Lopez; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

4.  Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.

Authors:  Daniel H Solomon; Elizabeth W Karlson; Eric B Rimm; Carolyn C Cannuscio; Lisa A Mandl; JoAnn E Manson; Meir J Stampfer; Gary C Curhan
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

5.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors:  Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

6.  Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort.

Authors:  Nicola J Goodson; Deborah P M Symmons; David G I Scott; Diane Bunn; Mark Lunt; Alan J Silman
Journal:  Arthritis Rheum       Date:  2005-08

7.  Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects.

Authors:  Inmaculada Del Rincón; Ken Williams; Michael P Stern; Gregory L Freeman; Daniel H O'Leary; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2003-07

Review 8.  Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.

Authors:  E K Schimmel; Y Yazici
Journal:  Clin Exp Rheumatol       Date:  2009 May-Jun       Impact factor: 4.473

9.  Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

Authors:  A Gonzalez; H Maradit Kremers; C S Crowson; K V Ballman; V L Roger; S J Jacobsen; W M O'Fallon; S E Gabriel
Journal:  Ann Rheum Dis       Date:  2007-05-21       Impact factor: 19.103

10.  Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.

Authors:  T Sokka; T Pincus
Journal:  Rheumatology (Oxford)       Date:  2008-08-07       Impact factor: 7.580

View more
  2 in total

1.  Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A Cross-Sectional Study.

Authors:  Vasyl Yagensky; Michael Schirmer
Journal:  Front Med (Lausanne)       Date:  2022-02-22

2.  Long-term outcomes in Rheumatoid Arthritis: Review of data from the 'Basildon Inflammatory Arthritis Cohort'.

Authors:  Kanishk Jain; Deena Laila; Anupama Nandagudi; Anurag Bharadwaj
Journal:  Rheumatol Adv Pract       Date:  2022-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.